 The FDA has accepted InVivo Therapeutics Holdings Corps NASDAQ: NVIV preclinical module, which is one of three individual modules required for the Companys humanitarian device exemption HDE application for its Neuro-Spinal Scaffold implant. Acceptance of the module indicates that FDA has completed its review of this module of the HDE and has no outstanding questions. 